#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Gut Microbiota in RA and OA
2-1	4-7	Gut	abstract[2]	new[2]	_	_
2-2	8-18	Microbiota	abstract[2]	new[2]	_	_
2-3	19-21	in	abstract[2]	new[2]	_	_
2-4	22-24	RA	abstract[2]|organization	new[2]|new	coref	3-18
2-5	25-28	and	abstract[2]	new[2]	_	_
2-6	29-31	OA	abstract[2]|abstract	new[2]|new	coref	22-8

#Text=The hypothesis that not only oral but also intestinal microbiota can be associated with the development of RA is supported by many data . Zhang et al. published a case-control metagenome-wide association study ( MGWAS ) of the fecal , dental and salivary microbiomes of a cohort of treatment-naive and treated RA patients .
3-1	32-35	The	abstract[5]	new[5]	_	_
3-2	36-46	hypothesis	abstract[5]	new[5]	_	_
3-3	47-51	that	abstract[5]	new[5]	_	_
3-4	52-55	not	abstract[5]	new[5]	_	_
3-5	56-60	only	abstract[5]	new[5]	_	_
3-6	61-65	oral	abstract[5]	new[5]	_	_
3-7	66-69	but	abstract[5]	new[5]	_	_
3-8	70-74	also	abstract[5]	new[5]	_	_
3-9	75-85	intestinal	abstract[5]|abstract[6]	new[5]|new[6]	coref	5-31[0_6]
3-10	86-96	microbiota	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-11	97-100	can	_	_	_	_
3-12	101-103	be	_	_	_	_
3-13	104-114	associated	_	_	_	_
3-14	115-119	with	_	_	_	_
3-15	120-123	the	event[7]	new[7]	_	_
3-16	124-135	development	event[7]	new[7]	_	_
3-17	136-138	of	event[7]	new[7]	_	_
3-18	139-141	RA	event[7]|organization	new[7]|giv	coref	3-52
3-19	142-144	is	_	_	_	_
3-20	145-154	supported	_	_	_	_
3-21	155-157	by	_	_	_	_
3-22	158-162	many	abstract[9]	new[9]	_	_
3-23	163-167	data	abstract[9]	new[9]	_	_
3-24	168-169	.	_	_	_	_
3-25	170-175	Zhang	_	_	_	_
3-26	176-178	et	_	_	_	_
3-27	179-182	al.	_	_	_	_
3-28	183-192	published	_	_	_	_
3-29	193-194	a	abstract[11]	new[11]	appos	3-35[0_11]
3-30	195-207	case-control	abstract[11]	new[11]	_	_
3-31	208-223	metagenome-wide	abstract[11]	new[11]	_	_
3-32	224-235	association	organization|abstract[11]	new|new[11]	_	_
3-33	236-241	study	abstract[11]	new[11]	_	_
3-34	242-243	(	_	_	_	_
3-35	244-249	MGWAS	abstract	giv	coref	5-2[23_0]
3-36	250-251	)	_	_	_	_
3-37	252-254	of	_	_	_	_
3-38	255-258	the	substance[13]|abstract[14]	new[13]|new[14]	coref|coref|coref|coref	5-14[27_13]|5-14[28_14]|5-14[27_13]|5-14[28_14]
3-39	259-264	fecal	substance[13]|abstract[14]	new[13]|new[14]	_	_
3-40	265-266	,	abstract[14]	new[14]	_	_
3-41	267-273	dental	abstract[14]|object[15]	new[14]|new[15]	_	_
3-42	274-277	and	abstract[14]|object[15]	new[14]|new[15]	_	_
3-43	278-286	salivary	abstract[14]|object[15]	new[14]|new[15]	_	_
3-44	287-298	microbiomes	abstract[14]|object[15]	new[14]|new[15]	_	_
3-45	299-301	of	abstract[14]|object[15]	new[14]|new[15]	_	_
3-46	302-303	a	abstract[14]|object[15]|person[16]	new[14]|new[15]|new[16]	_	_
3-47	304-310	cohort	abstract[14]|object[15]|person[16]	new[14]|new[15]|new[16]	_	_
3-48	311-313	of	abstract[14]|object[15]|person[16]	new[14]|new[15]|new[16]	_	_
3-49	314-329	treatment-naive	abstract[14]|object[15]|person[16]|person[18]	new[14]|new[15]|new[16]|new[18]	ana	4-1[0_18]
3-50	330-333	and	abstract[14]|object[15]|person[16]|person[18]	new[14]|new[15]|new[16]|new[18]	_	_
3-51	334-341	treated	abstract[14]|object[15]|person[16]|person[18]	new[14]|new[15]|new[16]|new[18]	_	_
3-52	342-344	RA	abstract[14]|object[15]|person[16]|organization|person[18]	new[14]|new[15]|new[16]|giv|new[18]	coref	5-12[26_0]
3-53	345-353	patients	abstract[14]|object[15]|person[16]|person[18]	new[14]|new[15]|new[16]|new[18]	_	_
3-54	354-355	.	_	_	_	_

#Text=They found that the RA-associated microbiome deviated significantly from healthy controls in all sites .
4-1	356-360	They	person	giv	coref	6-1[34_0]
4-2	361-366	found	_	_	_	_
4-3	367-371	that	_	_	_	_
4-4	372-375	the	abstract[20]	new[20]	coref	8-1[52_20]
4-5	376-389	RA-associated	abstract[20]	new[20]	_	_
4-6	390-400	microbiome	abstract[20]	new[20]	_	_
4-7	401-409	deviated	_	_	_	_
4-8	410-423	significantly	_	_	_	_
4-9	424-428	from	_	_	_	_
4-10	429-436	healthy	event[21]	new[21]	_	_
4-11	437-445	controls	event[21]	new[21]	_	_
4-12	446-448	in	event[21]	new[21]	_	_
4-13	449-452	all	event[21]|place[22]	new[21]|new[22]	coref	5-30[33_22]
4-14	453-458	sites	event[21]|place[22]	new[21]|new[22]	_	_
4-15	459-460	.	_	_	_	_

#Text=In this study , Haemophilus spp. was depleted in individuals with RA at the fecal and oral levels , whereas Lactobacillus salivarius was over-represented in individuals with RA at both microbiota sites .
5-1	461-463	In	_	_	_	_
5-2	464-468	this	abstract[23]	giv[23]	_	_
5-3	469-474	study	abstract[23]	giv[23]	_	_
5-4	475-476	,	_	_	_	_
5-5	477-488	Haemophilus	abstract	new	_	_
5-6	489-493	spp.	_	_	_	_
5-7	494-497	was	_	_	_	_
5-8	498-506	depleted	_	_	_	_
5-9	507-509	in	_	_	_	_
5-10	510-521	individuals	person[25]	new[25]	coref	5-26[30_25]
5-11	522-526	with	person[25]	new[25]	_	_
5-12	527-529	RA	person[25]|organization[26]	new[25]|giv[26]	coref	5-28[0_26]
5-13	530-532	at	person[25]|organization[26]	new[25]|giv[26]	_	_
5-14	533-536	the	person[25]|organization[26]|substance[27]|abstract[28]	new[25]|giv[26]|giv[27]|giv[28]	_	_
5-15	537-542	fecal	person[25]|organization[26]|substance[27]|abstract[28]	new[25]|giv[26]|giv[27]|giv[28]	_	_
5-16	543-546	and	person[25]|organization[26]|abstract[28]	new[25]|giv[26]|giv[28]	_	_
5-17	547-551	oral	person[25]|organization[26]|abstract[28]|abstract[29]	new[25]|giv[26]|giv[28]|new[29]	_	_
5-18	552-558	levels	person[25]|organization[26]|abstract[28]|abstract[29]	new[25]|giv[26]|giv[28]|new[29]	_	_
5-19	559-560	,	_	_	_	_
5-20	561-568	whereas	_	_	_	_
5-21	569-582	Lactobacillus	_	_	_	_
5-22	583-593	salivarius	_	_	_	_
5-23	594-597	was	_	_	_	_
5-24	598-614	over-represented	_	_	_	_
5-25	615-617	in	_	_	_	_
5-26	618-629	individuals	person[30]	giv[30]	_	_
5-27	630-634	with	person[30]	giv[30]	_	_
5-28	635-637	RA	person[30]|organization	giv[30]|giv	ana	6-10
5-29	638-640	at	person[30]	giv[30]	_	_
5-30	641-645	both	person[30]|place[33]	giv[30]|giv[33]	_	_
5-31	646-656	microbiota	person[30]|abstract|place[33]	giv[30]|giv|giv[33]	coref	7-3[40_0]
5-32	657-662	sites	person[30]|place[33]	giv[30]|giv[33]	_	_
5-33	663-664	.	_	_	_	_

#Text=Older patients often manifest more severe diseases , and this appears connected to age-related gut dysbiosis .
6-1	665-670	Older	person[34]	giv[34]	coref	10-38[85_34]
6-2	671-679	patients	person[34]	giv[34]	_	_
6-3	680-685	often	_	_	_	_
6-4	686-694	manifest	_	_	_	_
6-5	695-699	more	abstract[35]	new[35]	coref	8-13[0_35]
6-6	700-706	severe	abstract[35]	new[35]	_	_
6-7	707-715	diseases	abstract[35]	new[35]	_	_
6-8	716-717	,	_	_	_	_
6-9	718-721	and	_	_	_	_
6-10	722-726	this	organization	giv	coref	9-28
6-11	727-734	appears	_	_	_	_
6-12	735-744	connected	_	_	_	_
6-13	745-747	to	_	_	_	_
6-14	748-759	age-related	abstract[38]	new[38]	_	_
6-15	760-763	gut	abstract|abstract[38]	new|new[38]	coref	11-8
6-16	764-773	dysbiosis	abstract[38]	new[38]	_	_
6-17	774-775	.	_	_	_	_

#Text=Alterations in the microbiota provide plausible candidate mechanisms for driving both inflammation and altering the immune response and host metabolism , which in turn may modulate the development of musculoskeletal problems ( see the Prevotella copri case below ) .
7-1	776-787	Alterations	abstract[39]	new[39]	coref	20-22[173_39]
7-2	788-790	in	abstract[39]	new[39]	_	_
7-3	791-794	the	abstract[39]|abstract[40]	new[39]|giv[40]	coref	9-3[62_40]
7-4	795-805	microbiota	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
7-5	806-813	provide	_	_	_	_
7-6	814-823	plausible	abstract[42]	new[42]	coref	11-18[91_42]
7-7	824-833	candidate	person|abstract[42]	new|new[42]	_	_
7-8	834-844	mechanisms	abstract[42]	new[42]	_	_
7-9	845-848	for	_	_	_	_
7-10	849-856	driving	_	_	_	_
7-11	857-861	both	abstract[43]	new[43]	coref	18-18[0_43]
7-12	862-874	inflammation	abstract[43]	new[43]	_	_
7-13	875-878	and	_	_	_	_
7-14	879-887	altering	_	_	_	_
7-15	888-891	the	abstract[44]	new[44]	_	_
7-16	892-898	immune	abstract[44]	new[44]	_	_
7-17	899-907	response	abstract[44]	new[44]	_	_
7-18	908-911	and	_	_	_	_
7-19	912-916	host	person|abstract[46]	new|new[46]	_	_
7-20	917-927	metabolism	abstract[46]	new[46]	_	_
7-21	928-929	,	_	_	_	_
7-22	930-935	which	_	_	_	_
7-23	936-938	in	_	_	_	_
7-24	939-943	turn	_	_	_	_
7-25	944-947	may	_	_	_	_
7-26	948-956	modulate	_	_	_	_
7-27	957-960	the	event[47]	new[47]	_	_
7-28	961-972	development	event[47]	new[47]	_	_
7-29	973-975	of	event[47]	new[47]	_	_
7-30	976-991	musculoskeletal	event[47]|abstract[48]	new[47]|new[48]	_	_
7-31	992-1000	problems	event[47]|abstract[48]	new[47]|new[48]	_	_
7-32	1001-1002	(	_	_	_	_
7-33	1003-1006	see	_	_	_	_
7-34	1007-1010	the	abstract[51]	new[51]	_	_
7-35	1011-1021	Prevotella	object|abstract[51]	new|new[51]	coref	18-44
7-36	1022-1027	copri	person|abstract[51]	new|new[51]	coref	19-2[164_0]
7-37	1028-1032	case	abstract[51]	new[51]	_	_
7-38	1033-1038	below	_	_	_	_
7-39	1039-1040	)	_	_	_	_
7-40	1041-1042	.	_	_	_	_

#Text=The microbiome is thus a highly plausible target for the modulation of diseases of aging owing to its close relationship with innate and adaptive immune systems .
8-1	1043-1046	The	abstract[52]	giv[52]	coref	8-4[53_52]
8-2	1047-1057	microbiome	abstract[52]	giv[52]	_	_
8-3	1058-1060	is	_	_	_	_
8-4	1061-1065	thus	abstract[53]	giv[53]	coref	20-24[174_53]
8-5	1066-1067	a	abstract[53]	giv[53]	_	_
8-6	1068-1074	highly	abstract[53]	giv[53]	_	_
8-7	1075-1084	plausible	abstract[53]	giv[53]	_	_
8-8	1085-1091	target	abstract[53]	giv[53]	_	_
8-9	1092-1095	for	abstract[53]	giv[53]	_	_
8-10	1096-1099	the	abstract[53]|abstract[54]	giv[53]|new[54]	coref	14-5[0_54]
8-11	1100-1110	modulation	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
8-12	1111-1113	of	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
8-13	1114-1122	diseases	abstract[53]|abstract[54]|abstract	giv[53]|new[54]|giv	coref	9-25[69_0]
8-14	1123-1125	of	_	_	_	_
8-15	1126-1131	aging	abstract	new	ana	8-18
8-16	1132-1137	owing	_	_	_	_
8-17	1138-1140	to	_	_	_	_
8-18	1141-1144	its	abstract|abstract[58]	giv|new[58]	_	_
8-19	1145-1150	close	abstract[58]	new[58]	_	_
8-20	1151-1163	relationship	abstract[58]	new[58]	_	_
8-21	1164-1168	with	abstract[58]	new[58]	_	_
8-22	1169-1175	innate	abstract[58]|abstract[60]	new[58]|new[60]	_	_
8-23	1176-1179	and	abstract[58]|abstract[60]	new[58]|new[60]	_	_
8-24	1180-1188	adaptive	abstract[58]|abstract[60]	new[58]|new[60]	_	_
8-25	1189-1195	immune	abstract[58]|abstract|abstract[60]	new[58]|new|new[60]	coref	28-23
8-26	1196-1203	systems	abstract[58]|abstract[60]	new[58]|new[60]	_	_
8-27	1204-1205	.	_	_	_	_

#Text=Components of intestinal microbiota can indeed direct key aspects of host immunity , in particular effector T-cell differentiation , which may impact susceptibility to autoimmune diseases and RA in particular .
9-1	1206-1216	Components	object[61]	new[61]	_	_
9-2	1217-1219	of	object[61]	new[61]	_	_
9-3	1220-1230	intestinal	object[61]|abstract[62]	new[61]|giv[62]	coref	11-7[88_62]
9-4	1231-1241	microbiota	object[61]|abstract[62]	new[61]|giv[62]	_	_
9-5	1242-1245	can	_	_	_	_
9-6	1246-1252	indeed	_	_	_	_
9-7	1253-1259	direct	_	_	_	_
9-8	1260-1263	key	abstract[63]	new[63]	_	_
9-9	1264-1271	aspects	abstract[63]	new[63]	_	_
9-10	1272-1274	of	abstract[63]	new[63]	_	_
9-11	1275-1279	host	abstract[63]|abstract[64]	new[63]|new[64]	_	_
9-12	1280-1288	immunity	abstract[63]|abstract[64]	new[63]|new[64]	_	_
9-13	1289-1290	,	abstract[63]|abstract[64]	new[63]|new[64]	_	_
9-14	1291-1293	in	abstract[63]|abstract[64]	new[63]|new[64]	_	_
9-15	1294-1304	particular	abstract[63]|abstract[64]|abstract[66]	new[63]|new[64]|new[66]	coref	11-25[92_66]
9-16	1305-1313	effector	abstract[63]|abstract[64]|person|abstract[66]	new[63]|new[64]|new|new[66]	_	_
9-17	1314-1320	T-cell	abstract[63]|abstract[64]|abstract[66]	new[63]|new[64]|new[66]	_	_
9-18	1321-1336	differentiation	abstract[63]|abstract[64]|abstract[66]	new[63]|new[64]|new[66]	_	_
9-19	1337-1338	,	_	_	_	_
9-20	1339-1344	which	_	_	_	_
9-21	1345-1348	may	_	_	_	_
9-22	1349-1355	impact	_	_	_	_
9-23	1356-1370	susceptibility	abstract[67]	new[67]	_	_
9-24	1371-1373	to	abstract[67]	new[67]	_	_
9-25	1374-1384	autoimmune	abstract[67]|object|abstract[69]	new[67]|new|giv[69]	coref|coref	12-47[112_69]|12-47[112_69]
9-26	1385-1393	diseases	abstract[67]|abstract[69]	new[67]|giv[69]	_	_
9-27	1394-1397	and	abstract[67]|abstract[69]	new[67]|giv[69]	_	_
9-28	1398-1400	RA	abstract[67]|abstract[69]|organization	new[67]|giv[69]|giv	coref	10-7
9-29	1401-1403	in	_	_	_	_
9-30	1404-1414	particular	_	_	_	_
9-31	1415-1416	.	_	_	_	_

#Text=Different studies investigating the etiology of RA have established the involvement of regulatory T ( T-reg ) cells , which are defective at suppressing IFN-γ and TNF-α production by conventional T cells in the peripheral blood of active RA patients .
10-1	1417-1426	Different	abstract[71]	new[71]	coref	20-1[171_71]
10-2	1427-1434	studies	abstract[71]	new[71]	_	_
10-3	1435-1448	investigating	_	_	_	_
10-4	1449-1452	the	abstract[72]	new[72]	_	_
10-5	1453-1461	etiology	abstract[72]	new[72]	_	_
10-6	1462-1464	of	abstract[72]	new[72]	_	_
10-7	1465-1467	RA	abstract[72]|organization	new[72]|giv	coref	10-39
10-8	1468-1472	have	_	_	_	_
10-9	1473-1484	established	_	_	_	_
10-10	1485-1488	the	abstract[74]	new[74]	_	_
10-11	1489-1500	involvement	abstract[74]	new[74]	_	_
10-12	1501-1503	of	abstract[74]	new[74]	_	_
10-13	1504-1514	regulatory	abstract[74]|person[75]	new[74]|new[75]	coref	10-31[0_75]
10-14	1515-1516	T	abstract[74]|person[75]	new[74]|new[75]	_	_
10-15	1517-1518	(	abstract[74]	new[74]	_	_
10-16	1519-1524	T-reg	abstract[74]|abstract	new[74]|new	coref	11-34
10-17	1525-1526	)	abstract[74]	new[74]	_	_
10-18	1527-1532	cells	abstract[74]|object	new[74]|new	coref	10-30[82_0]
10-19	1533-1534	,	_	_	_	_
10-20	1535-1540	which	_	_	_	_
10-21	1541-1544	are	_	_	_	_
10-22	1545-1554	defective	_	_	_	_
10-23	1555-1557	at	_	_	_	_
10-24	1558-1569	suppressing	_	_	_	_
10-25	1570-1575	IFN-γ	abstract	new	_	_
10-26	1576-1579	and	_	_	_	_
10-27	1580-1585	TNF-α	object|abstract[80]	new|new[80]	ana|ana	11-1[0_80]|11-1[0_80]
10-28	1586-1596	production	abstract[80]	new[80]	_	_
10-29	1597-1599	by	_	_	_	_
10-30	1600-1612	conventional	object[82]	giv[82]	coref	11-33[96_82]
10-31	1613-1614	T	person|object[82]	giv|giv[82]	coref	14-14
10-32	1615-1620	cells	object[82]	giv[82]	_	_
10-33	1621-1623	in	object[82]	giv[82]	_	_
10-34	1624-1627	the	object[82]|substance[83]	giv[82]|new[83]	_	_
10-35	1628-1638	peripheral	object[82]|substance[83]	giv[82]|new[83]	_	_
10-36	1639-1644	blood	object[82]|substance[83]	giv[82]|new[83]	_	_
10-37	1645-1647	of	object[82]|substance[83]	giv[82]|new[83]	_	_
10-38	1648-1654	active	object[82]|substance[83]|person[85]	giv[82]|new[83]|giv[85]	coref	18-40[160_85]
10-39	1655-1657	RA	object[82]|substance[83]|organization|person[85]	giv[82]|new[83]|giv|giv[85]	coref	17-20
10-40	1658-1666	patients	object[82]|substance[83]|person[85]	giv[82]|new[83]|giv[85]	_	_
10-41	1667-1668	.	_	_	_	_

#Text=It has been well established that the gut microbiota – immune interaction and homeostasis , via balancing pro- and anti-inflammatory mechanisms , can regulate the differentiation of various T cell types , especially T-reg cells .
11-1	1669-1671	It	abstract	giv	_	_
11-2	1672-1675	has	_	_	_	_
11-3	1676-1680	been	_	_	_	_
11-4	1681-1685	well	_	_	_	_
11-5	1686-1697	established	_	_	_	_
11-6	1698-1702	that	_	_	_	_
11-7	1703-1706	the	abstract[88]	giv[88]	coref	15-6[0_88]
11-8	1707-1710	gut	abstract|abstract[88]	giv|giv[88]	coref	16-9
11-9	1711-1721	microbiota	abstract[88]	giv[88]	_	_
11-10	1722-1723	–	_	_	_	_
11-11	1724-1730	immune	event[89]	new[89]	_	_
11-12	1731-1742	interaction	event[89]	new[89]	_	_
11-13	1743-1746	and	_	_	_	_
11-14	1747-1758	homeostasis	abstract	new	_	_
11-15	1759-1760	,	_	_	_	_
11-16	1761-1764	via	_	_	_	_
11-17	1765-1774	balancing	_	_	_	_
11-18	1775-1779	pro-	abstract[91]	giv[91]	_	_
11-19	1780-1783	and	abstract[91]	giv[91]	_	_
11-20	1784-1801	anti-inflammatory	abstract[91]	giv[91]	_	_
11-21	1802-1812	mechanisms	abstract[91]	giv[91]	_	_
11-22	1813-1814	,	_	_	_	_
11-23	1815-1818	can	_	_	_	_
11-24	1819-1827	regulate	_	_	_	_
11-25	1828-1831	the	abstract[92]	giv[92]	coref	12-35[108_92]
11-26	1832-1847	differentiation	abstract[92]	giv[92]	_	_
11-27	1848-1850	of	abstract[92]	giv[92]	_	_
11-28	1851-1858	various	abstract[92]|abstract[94]	giv[92]|new[94]	_	_
11-29	1859-1860	T	abstract[92]|abstract[94]	giv[92]|new[94]	_	_
11-30	1861-1865	cell	abstract[92]|object|abstract[94]	giv[92]|new|new[94]	coref	12-36
11-31	1866-1871	types	abstract[92]|abstract[94]	giv[92]|new[94]	_	_
11-32	1872-1873	,	_	_	_	_
11-33	1874-1884	especially	object[96]	giv[96]	coref	14-14[128_96]
11-34	1885-1890	T-reg	object|object[96]	giv|giv[96]	coref	12-35
11-35	1891-1896	cells	object[96]	giv[96]	_	_
11-36	1897-1898	.	_	_	_	_

#Text=A clear example is the potential therapeutic effect of SCFAs ( short chain fatty acids ) , which are microbial fermentation products found in the bowel , that have demonstrated a profound influence on T-reg cell differentiation in a variety of experimental models of autoimmunity or inflammatory T-cell-mediated diseases .
12-1	1899-1900	A	abstract[97]	new[97]	coref	12-5[98_97]
12-2	1901-1906	clear	abstract[97]	new[97]	_	_
12-3	1907-1914	example	abstract[97]	new[97]	_	_
12-4	1915-1917	is	_	_	_	_
12-5	1918-1921	the	abstract[98]	giv[98]	_	_
12-6	1922-1931	potential	abstract[98]	giv[98]	_	_
12-7	1932-1943	therapeutic	abstract[98]	giv[98]	_	_
12-8	1944-1950	effect	abstract[98]	giv[98]	_	_
12-9	1951-1953	of	abstract[98]	giv[98]	_	_
12-10	1954-1959	SCFAs	abstract[98]|abstract	giv[98]|new	_	_
12-11	1960-1961	(	_	_	_	_
12-12	1962-1967	short	substance[101]	new[101]	_	_
12-13	1968-1973	chain	substance[101]	new[101]	_	_
12-14	1974-1979	fatty	abstract|substance[101]	new|new[101]	_	_
12-15	1980-1985	acids	substance[101]	new[101]	_	_
12-16	1986-1987	)	_	_	_	_
12-17	1988-1989	,	_	_	_	_
12-18	1990-1995	which	_	_	_	_
12-19	1996-1999	are	_	_	_	_
12-20	2000-2009	microbial	abstract[103]	new[103]	_	_
12-21	2010-2022	fermentation	abstract|abstract[103]	new|new[103]	_	_
12-22	2023-2031	products	abstract[103]	new[103]	_	_
12-23	2032-2037	found	_	_	_	_
12-24	2038-2040	in	_	_	_	_
12-25	2041-2044	the	object[104]	new[104]	_	_
12-26	2045-2050	bowel	object[104]	new[104]	_	_
12-27	2051-2052	,	_	_	_	_
12-28	2053-2057	that	_	_	_	_
12-29	2058-2062	have	_	_	_	_
12-30	2063-2075	demonstrated	_	_	_	_
12-31	2076-2077	a	abstract[105]	new[105]	_	_
12-32	2078-2086	profound	abstract[105]	new[105]	_	_
12-33	2087-2096	influence	abstract[105]	new[105]	_	_
12-34	2097-2099	on	abstract[105]	new[105]	_	_
12-35	2100-2105	T-reg	abstract[105]|object|abstract[108]	new[105]|giv|giv[108]	coref|coref	14-17|14-17
12-36	2106-2110	cell	abstract[105]|place|abstract[108]	new[105]|giv|giv[108]	_	_
12-37	2111-2126	differentiation	abstract[105]|abstract[108]	new[105]|giv[108]	_	_
12-38	2127-2129	in	abstract[105]|abstract[108]	new[105]|giv[108]	_	_
12-39	2130-2131	a	abstract[105]|abstract[108]|abstract[109]	new[105]|giv[108]|new[109]	_	_
12-40	2132-2139	variety	abstract[105]|abstract[108]|abstract[109]	new[105]|giv[108]|new[109]	_	_
12-41	2140-2142	of	abstract[105]|abstract[108]|abstract[109]	new[105]|giv[108]|new[109]	_	_
12-42	2143-2155	experimental	abstract[105]|abstract[108]|abstract[109]|abstract[110]	new[105]|giv[108]|new[109]|new[110]	_	_
12-43	2156-2162	models	abstract[105]|abstract[108]|abstract[109]|abstract[110]	new[105]|giv[108]|new[109]|new[110]	_	_
12-44	2163-2165	of	abstract[105]|abstract[108]|abstract[109]|abstract[110]	new[105]|giv[108]|new[109]|new[110]	_	_
12-45	2166-2178	autoimmunity	abstract[105]|abstract[108]|abstract[109]|abstract[110]|abstract	new[105]|giv[108]|new[109]|new[110]|new	_	_
12-46	2179-2181	or	abstract[105]|abstract[108]|abstract[109]|abstract[110]	new[105]|giv[108]|new[109]|new[110]	_	_
12-47	2182-2194	inflammatory	abstract[105]|abstract[108]|abstract[109]|abstract[110]|abstract[112]	new[105]|giv[108]|new[109]|new[110]|giv[112]	_	_
12-48	2195-2210	T-cell-mediated	abstract[105]|abstract[108]|abstract[109]|abstract[110]|abstract[112]	new[105]|giv[108]|new[109]|new[110]|giv[112]	_	_
12-49	2211-2219	diseases	abstract[105]|abstract[108]|abstract[109]|abstract[110]|abstract[112]	new[105]|giv[108]|new[109]|new[110]|giv[112]	_	_
12-50	2220-2221	.	_	_	_	_

#Text=An elegant collagen-induced arthritis mouse model published by Hui et al. demonstrated that butyrate ( a functional SCFA ) administration inhibited arthritis by suppressing the expression of inflammatory cytokines .
13-1	2222-2224	An	abstract[115]	new[115]	_	_
13-2	2225-2232	elegant	abstract[115]	new[115]	_	_
13-3	2233-2249	collagen-induced	abstract[115]	new[115]	_	_
13-4	2250-2259	arthritis	abstract|abstract[115]	new|new[115]	coref	13-22
13-5	2260-2265	mouse	animal|abstract[115]	new|new[115]	_	_
13-6	2266-2271	model	abstract[115]	new[115]	_	_
13-7	2272-2281	published	_	_	_	_
13-8	2282-2284	by	_	_	_	_
13-9	2285-2288	Hui	person	new	_	_
13-10	2289-2291	et	_	_	_	_
13-11	2292-2295	al.	_	_	_	_
13-12	2296-2308	demonstrated	_	_	_	_
13-13	2309-2313	that	_	_	_	_
13-14	2314-2322	butyrate	substance[117]	new[117]	_	_
13-15	2323-2324	(	substance[117]|organization[119]	new[117]|new[119]	_	_
13-16	2325-2326	a	substance[117]|organization[119]	new[117]|new[119]	_	_
13-17	2327-2337	functional	substance[117]|substance[118]|organization[119]	new[117]|new[118]|new[119]	_	_
13-18	2338-2342	SCFA	substance[117]|substance[118]|organization[119]	new[117]|new[118]|new[119]	_	_
13-19	2343-2344	)	substance[117]|organization[119]	new[117]|new[119]	_	_
13-20	2345-2359	administration	substance[117]|organization[119]	new[117]|new[119]	_	_
13-21	2360-2369	inhibited	_	_	_	_
13-22	2370-2379	arthritis	abstract	giv	coref	15-13[138_0]
13-23	2380-2382	by	_	_	_	_
13-24	2383-2394	suppressing	_	_	_	_
13-25	2395-2398	the	abstract[121]	new[121]	_	_
13-26	2399-2409	expression	abstract[121]	new[121]	_	_
13-27	2410-2412	of	abstract[121]	new[121]	_	_
13-28	2413-2425	inflammatory	abstract[121]|abstract[122]	new[121]|new[122]	_	_
13-29	2426-2435	cytokines	abstract[121]|abstract[122]	new[121]|new[122]	_	_
13-30	2436-2437	.	_	_	_	_

#Text=The authors suggested that modulation was likely mediated by the differentiation of CD4 T cells towards T-reg cells , which produce anti-inflammatory cytokine IL-10 , and thus influenced the function of Th17 cells .
14-1	2438-2441	The	person[123]	new[123]	_	_
14-2	2442-2449	authors	person[123]	new[123]	_	_
14-3	2450-2459	suggested	_	_	_	_
14-4	2460-2464	that	_	_	_	_
14-5	2465-2475	modulation	abstract	giv	_	_
14-6	2476-2479	was	_	_	_	_
14-7	2480-2486	likely	_	_	_	_
14-8	2487-2495	mediated	_	_	_	_
14-9	2496-2498	by	_	_	_	_
14-10	2499-2502	the	abstract[125]	new[125]	_	_
14-11	2503-2518	differentiation	abstract[125]	new[125]	_	_
14-12	2519-2521	of	abstract[125]	new[125]	_	_
14-13	2522-2525	CD4	abstract[125]|abstract	new[125]|new	_	_
14-14	2526-2527	T	abstract[125]|person|object[128]	new[125]|giv|giv[128]	coref|coref	14-17[130_128]|14-17[130_128]
14-15	2528-2533	cells	abstract[125]|object[128]	new[125]|giv[128]	_	_
14-16	2534-2541	towards	abstract[125]	new[125]	_	_
14-17	2542-2547	T-reg	abstract[125]|object|object[130]	new[125]|giv|giv[130]	coref|coref	14-32[135_130]|14-32[135_130]
14-18	2548-2553	cells	abstract[125]|object[130]	new[125]|giv[130]	_	_
14-19	2554-2555	,	_	_	_	_
14-20	2556-2561	which	_	_	_	_
14-21	2562-2569	produce	_	_	_	_
14-22	2570-2587	anti-inflammatory	time[132]	new[132]	_	_
14-23	2588-2596	cytokine	abstract|time[132]	new|new[132]	_	_
14-24	2597-2602	IL-10	time[132]	new[132]	_	_
14-25	2603-2604	,	_	_	_	_
14-26	2605-2608	and	_	_	_	_
14-27	2609-2613	thus	_	_	_	_
14-28	2614-2624	influenced	_	_	_	_
14-29	2625-2628	the	abstract[133]	new[133]	_	_
14-30	2629-2637	function	abstract[133]	new[133]	_	_
14-31	2638-2640	of	abstract[133]	new[133]	_	_
14-32	2641-2645	Th17	abstract[133]|substance|object[135]	new[133]|new|giv[135]	_	_
14-33	2646-2651	cells	abstract[133]|object[135]	new[133]|giv[135]	_	_
14-34	2652-2653	.	_	_	_	_

#Text=As mentioned , an altered microbiota profile has also been associated with juvenile idiopathic arthritis ( JIA ) .
15-1	2654-2656	As	_	_	_	_
15-2	2657-2666	mentioned	_	_	_	_
15-3	2667-2668	,	_	_	_	_
15-4	2669-2671	an	abstract[137]	new[137]	_	_
15-5	2672-2679	altered	abstract[137]	new[137]	_	_
15-6	2680-2690	microbiota	abstract|abstract[137]	giv|new[137]	coref	16-9[143_0]
15-7	2691-2698	profile	abstract[137]	new[137]	_	_
15-8	2699-2702	has	_	_	_	_
15-9	2703-2707	also	_	_	_	_
15-10	2708-2712	been	_	_	_	_
15-11	2713-2723	associated	_	_	_	_
15-12	2724-2728	with	_	_	_	_
15-13	2729-2737	juvenile	abstract[138]	giv[138]	_	_
15-14	2738-2748	idiopathic	abstract[138]	giv[138]	_	_
15-15	2749-2758	arthritis	abstract[138]	giv[138]	_	_
15-16	2759-2760	(	_	_	_	_
15-17	2761-2764	JIA	person	new	coref	16-17
15-18	2765-2766	)	_	_	_	_
15-19	2767-2768	.	_	_	_	_

#Text=Current evidence indeed suggests that the perturbation of gut microbiota may contribute to the development of JIA .
16-1	2769-2776	Current	abstract[140]	new[140]	_	_
16-2	2777-2785	evidence	abstract[140]	new[140]	_	_
16-3	2786-2792	indeed	_	_	_	_
16-4	2793-2801	suggests	_	_	_	_
16-5	2802-2806	that	_	_	_	_
16-6	2807-2810	the	abstract[141]	new[141]	_	_
16-7	2811-2823	perturbation	abstract[141]	new[141]	_	_
16-8	2824-2826	of	abstract[141]	new[141]	_	_
16-9	2827-2830	gut	abstract[141]|abstract|abstract[143]	new[141]|giv|giv[143]	coref|coref|coref|coref	21-4[181_143]|26-25|21-4[181_143]|26-25
16-10	2831-2841	microbiota	abstract[141]|abstract[143]	new[141]|giv[143]	_	_
16-11	2842-2845	may	_	_	_	_
16-12	2846-2856	contribute	_	_	_	_
16-13	2857-2859	to	_	_	_	_
16-14	2860-2863	the	event[144]	new[144]	ana	17-1[0_144]
16-15	2864-2875	development	event[144]	new[144]	_	_
16-16	2876-2878	of	event[144]	new[144]	_	_
16-17	2879-2882	JIA	event[144]|person	new[144]|giv	_	_
16-18	2883-2884	.	_	_	_	_

#Text=It remains difficult , however , to establish a definitive microbial marker or specific enterotypes that are associated with RA .
17-1	2885-2887	It	event	giv	_	_
17-2	2888-2895	remains	_	_	_	_
17-3	2896-2905	difficult	_	_	_	_
17-4	2906-2907	,	_	_	_	_
17-5	2908-2915	however	_	_	_	_
17-6	2916-2917	,	_	_	_	_
17-7	2918-2920	to	_	_	_	_
17-8	2921-2930	establish	_	_	_	_
17-9	2931-2932	a	abstract[147]	new[147]	ana	18-1[0_147]
17-10	2933-2943	definitive	abstract[147]	new[147]	_	_
17-11	2944-2953	microbial	abstract[147]	new[147]	_	_
17-12	2954-2960	marker	abstract[147]	new[147]	_	_
17-13	2961-2963	or	_	_	_	_
17-14	2964-2972	specific	object[148]	new[148]	_	_
17-15	2973-2984	enterotypes	object[148]	new[148]	_	_
17-16	2985-2989	that	_	_	_	_
17-17	2990-2993	are	_	_	_	_
17-18	2994-3004	associated	_	_	_	_
17-19	3005-3009	with	_	_	_	_
17-20	3010-3012	RA	organization	giv	coref	18-40
17-21	3013-3014	.	_	_	_	_

#Text=It has been hypothesized that the alteration of single bacterial genus could have direct impact on driving inflammation , as suggested for Bacteroides , Akkermansia or the anti-inflammatory Faecalobacterium prausnitzii , which has been noted to be depleted in RA patients , while Prevotella and Ruminococcus were more prevalent .
18-1	3015-3017	It	abstract	giv	_	_
18-2	3018-3021	has	_	_	_	_
18-3	3022-3026	been	_	_	_	_
18-4	3027-3039	hypothesized	_	_	_	_
18-5	3040-3044	that	_	_	_	_
18-6	3045-3048	the	event[151]	new[151]	_	_
18-7	3049-3059	alteration	event[151]	new[151]	_	_
18-8	3060-3062	of	event[151]	new[151]	_	_
18-9	3063-3069	single	event[151]|abstract[153]	new[151]|new[153]	_	_
18-10	3070-3079	bacterial	event[151]|substance|abstract[153]	new[151]|new|new[153]	coref	27-31
18-11	3080-3085	genus	event[151]|abstract[153]	new[151]|new[153]	_	_
18-12	3086-3091	could	_	_	_	_
18-13	3092-3096	have	_	_	_	_
18-14	3097-3103	direct	abstract[154]	new[154]	_	_
18-15	3104-3110	impact	abstract[154]	new[154]	_	_
18-16	3111-3113	on	_	_	_	_
18-17	3114-3121	driving	_	_	_	_
18-18	3122-3134	inflammation	abstract	giv	coref	31-6[254_0]
18-19	3135-3136	,	_	_	_	_
18-20	3137-3139	as	_	_	_	_
18-21	3140-3149	suggested	_	_	_	_
18-22	3150-3153	for	_	_	_	_
18-23	3154-3165	Bacteroides	abstract	new	coref	19-6
18-24	3166-3167	,	_	_	_	_
18-25	3168-3179	Akkermansia	person	new	_	_
18-26	3180-3182	or	_	_	_	_
18-27	3183-3186	the	_	_	_	_
18-28	3187-3204	anti-inflammatory	_	_	_	_
18-29	3205-3221	Faecalobacterium	animal	new	_	_
18-30	3222-3233	prausnitzii	_	_	_	_
18-31	3234-3235	,	_	_	_	_
18-32	3236-3241	which	_	_	_	_
18-33	3242-3245	has	_	_	_	_
18-34	3246-3250	been	_	_	_	_
18-35	3251-3256	noted	_	_	_	_
18-36	3257-3259	to	_	_	_	_
18-37	3260-3262	be	_	_	_	_
18-38	3263-3271	depleted	_	_	_	_
18-39	3272-3274	in	_	_	_	_
18-40	3275-3277	RA	organization|person[160]	giv|giv[160]	coref|coref|coref|coref	19-19[169_0]|31-73[277_160]|19-19[169_0]|31-73[277_160]
18-41	3278-3286	patients	person[160]	giv[160]	_	_
18-42	3287-3288	,	_	_	_	_
18-43	3289-3294	while	_	_	_	_
18-44	3295-3305	Prevotella	abstract	giv	coref	19-2
18-45	3306-3309	and	_	_	_	_
18-46	3310-3322	Ruminococcus	animal	new	_	_
18-47	3323-3327	were	_	_	_	_
18-48	3328-3332	more	_	_	_	_
18-49	3333-3342	prevalent	_	_	_	_
18-50	3343-3344	.	_	_	_	_

#Text=Increasing Prevotella copri and decreasing Bacteroides concentrations in the stool have both been associated with new onset , untreated RA in humans .
19-1	3345-3355	Increasing	_	_	_	_
19-2	3356-3366	Prevotella	substance|person[164]	giv|giv[164]	_	_
19-3	3367-3372	copri	person[164]	giv[164]	_	_
19-4	3373-3376	and	_	_	_	_
19-5	3377-3387	decreasing	animal[166]	new[166]	coref	31-50[269_166]
19-6	3388-3399	Bacteroides	substance|animal[166]	giv|new[166]	coref	26-32
19-7	3400-3414	concentrations	animal[166]	new[166]	_	_
19-8	3415-3417	in	animal[166]	new[166]	_	_
19-9	3418-3421	the	animal[166]|object[167]	new[166]|new[167]	_	_
19-10	3422-3427	stool	animal[166]|object[167]	new[166]|new[167]	_	_
19-11	3428-3432	have	_	_	_	_
19-12	3433-3437	both	_	_	_	_
19-13	3438-3442	been	_	_	_	_
19-14	3443-3453	associated	_	_	_	_
19-15	3454-3458	with	_	_	_	_
19-16	3459-3462	new	abstract[168]	new[168]	coref	31-66[274_168]
19-17	3463-3468	onset	abstract[168]	new[168]	_	_
19-18	3469-3470	,	_	_	_	_
19-19	3471-3480	untreated	organization[169]	giv[169]	_	_
19-20	3481-3483	RA	organization[169]	giv[169]	_	_
19-21	3484-3486	in	_	_	_	_
19-22	3487-3493	humans	person	new	_	_
19-23	3494-3495	.	_	_	_	_

#Text=The above studies , although not always homogenous , have directly or indirectly demonstrated that genetic risk may be modulated by alterations in the microbiome and that the presence of particular microbial markers can be predictive of disease .
20-1	3496-3499	The	abstract[171]	giv[171]	_	_
20-2	3500-3505	above	abstract[171]	giv[171]	_	_
20-3	3506-3513	studies	abstract[171]	giv[171]	_	_
20-4	3514-3515	,	_	_	_	_
20-5	3516-3524	although	_	_	_	_
20-6	3525-3528	not	_	_	_	_
20-7	3529-3535	always	_	_	_	_
20-8	3536-3546	homogenous	_	_	_	_
20-9	3547-3548	,	_	_	_	_
20-10	3549-3553	have	_	_	_	_
20-11	3554-3562	directly	_	_	_	_
20-12	3563-3565	or	_	_	_	_
20-13	3566-3576	indirectly	_	_	_	_
20-14	3577-3589	demonstrated	_	_	_	_
20-15	3590-3594	that	_	_	_	_
20-16	3595-3602	genetic	abstract[172]	new[172]	coref	24-14[0_172]
20-17	3603-3607	risk	abstract[172]	new[172]	_	_
20-18	3608-3611	may	_	_	_	_
20-19	3612-3614	be	_	_	_	_
20-20	3615-3624	modulated	_	_	_	_
20-21	3625-3627	by	_	_	_	_
20-22	3628-3639	alterations	abstract[173]	giv[173]	_	_
20-23	3640-3642	in	abstract[173]	giv[173]	_	_
20-24	3643-3646	the	abstract[173]|abstract[174]	giv[173]|giv[174]	coref	29-18[244_174]
20-25	3647-3657	microbiome	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
20-26	3658-3661	and	_	_	_	_
20-27	3662-3666	that	_	_	_	_
20-28	3667-3670	the	abstract[175]	new[175]	coref	20-36[178_175]
20-29	3671-3679	presence	abstract[175]	new[175]	_	_
20-30	3680-3682	of	abstract[175]	new[175]	_	_
20-31	3683-3693	particular	abstract[175]|abstract[177]	new[175]|new[177]	_	_
20-32	3694-3703	microbial	abstract[175]|place|abstract[177]	new[175]|new|new[177]	_	_
20-33	3704-3711	markers	abstract[175]|abstract[177]	new[175]|new[177]	_	_
20-34	3712-3715	can	_	_	_	_
20-35	3716-3718	be	_	_	_	_
20-36	3719-3729	predictive	abstract[178]	giv[178]	_	_
20-37	3730-3732	of	abstract[178]	giv[178]	_	_
20-38	3733-3740	disease	abstract[178]|abstract	giv[178]|new	coref	22-20
20-39	3741-3742	.	_	_	_	_

#Text=As mentioned , intestinal microbiota are also known to change with age .
21-1	3743-3745	As	_	_	_	_
21-2	3746-3755	mentioned	_	_	_	_
21-3	3756-3757	,	_	_	_	_
21-4	3758-3768	intestinal	person|abstract[181]	new|giv[181]	coref|coref	25-11[206_181]|25-11[206_181]
21-5	3769-3779	microbiota	abstract[181]	giv[181]	_	_
21-6	3780-3783	are	_	_	_	_
21-7	3784-3788	also	_	_	_	_
21-8	3789-3794	known	_	_	_	_
21-9	3795-3797	to	_	_	_	_
21-10	3798-3804	change	abstract	new	coref|none	22-13[185_0]|21-10[0_185]
21-11	3805-3809	with	_	_	_	_
21-12	3810-3813	age	abstract	new	coref	22-24
21-13	3814-3815	.	_	_	_	_

#Text=Many of the clinical issues , including OA , are related to the inflammatory change — either specific to disease or associated with age .
22-1	3816-3820	Many	_	_	_	_
22-2	3821-3823	of	_	_	_	_
22-3	3824-3827	the	abstract[183]	new[183]	_	_
22-4	3828-3836	clinical	abstract[183]	new[183]	_	_
22-5	3837-3843	issues	abstract[183]	new[183]	_	_
22-6	3844-3845	,	abstract[183]	new[183]	_	_
22-7	3846-3855	including	abstract[183]	new[183]	_	_
22-8	3856-3858	OA	abstract[183]|substance	new[183]|giv	coref	23-1
22-9	3859-3860	,	_	_	_	_
22-10	3861-3864	are	_	_	_	_
22-11	3865-3872	related	_	_	_	_
22-12	3873-3875	to	_	_	_	_
22-13	3876-3879	the	abstract[185]	new[185]	_	_
22-14	3880-3892	inflammatory	abstract[185]	new[185]	_	_
22-15	3893-3899	change	abstract[185]	new[185]	_	_
22-16	3900-3901	—	_	_	_	_
22-17	3902-3908	either	_	_	_	_
22-18	3909-3917	specific	_	_	_	_
22-19	3918-3920	to	_	_	_	_
22-20	3921-3928	disease	abstract	giv	coref	24-22[198_0]
22-21	3929-3931	or	_	_	_	_
22-22	3932-3942	associated	_	_	_	_
22-23	3943-3947	with	_	_	_	_
22-24	3948-3951	age	abstract	giv	coref	23-18[192_0]
22-25	3952-3953	.	_	_	_	_

#Text=OA is indeed considered a degeneration of joint cartilage and the underlying bone which commonly occurs from middle age onward .
23-1	3954-3956	OA	abstract	giv	coref	24-5
23-2	3957-3959	is	_	_	_	_
23-3	3960-3966	indeed	_	_	_	_
23-4	3967-3977	considered	_	_	_	_
23-5	3978-3979	a	event[189]	new[189]	_	_
23-6	3980-3992	degeneration	event[189]	new[189]	_	_
23-7	3993-3995	of	event[189]	new[189]	_	_
23-8	3996-4001	joint	event[189]|object[190]	new[189]|new[190]	_	_
23-9	4002-4011	cartilage	event[189]|object[190]	new[189]|new[190]	_	_
23-10	4012-4015	and	event[189]	new[189]	_	_
23-11	4016-4019	the	event[189]|object[191]	new[189]|new[191]	_	_
23-12	4020-4030	underlying	event[189]|object[191]	new[189]|new[191]	_	_
23-13	4031-4035	bone	event[189]|object[191]	new[189]|new[191]	_	_
23-14	4036-4041	which	_	_	_	_
23-15	4042-4050	commonly	_	_	_	_
23-16	4051-4057	occurs	_	_	_	_
23-17	4058-4062	from	_	_	_	_
23-18	4063-4069	middle	abstract[192]	giv[192]	coref	24-26[0_192]
23-19	4070-4073	age	abstract[192]	giv[192]	_	_
23-20	4074-4080	onward	_	_	_	_
23-21	4081-4082	.	_	_	_	_

#Text=The precise etiology of OA remains unknown thus far , even if various risk factors have been associated with presence of the disease , including age , sex , obesity , and diet , and local joint injury .
24-1	4083-4086	The	abstract[193]	new[193]	_	_
24-2	4087-4094	precise	abstract[193]	new[193]	_	_
24-3	4095-4103	etiology	abstract[193]	new[193]	_	_
24-4	4104-4106	of	abstract[193]	new[193]	_	_
24-5	4107-4109	OA	abstract[193]|abstract	new[193]|giv	coref	29-5
24-6	4110-4117	remains	_	_	_	_
24-7	4118-4125	unknown	_	_	_	_
24-8	4126-4130	thus	_	_	_	_
24-9	4131-4134	far	_	_	_	_
24-10	4135-4136	,	_	_	_	_
24-11	4137-4141	even	_	_	_	_
24-12	4142-4144	if	_	_	_	_
24-13	4145-4152	various	abstract[196]	new[196]	coref	25-1[204_196]
24-14	4153-4157	risk	abstract|abstract[196]	giv|new[196]	_	_
24-15	4158-4165	factors	abstract[196]	new[196]	_	_
24-16	4166-4170	have	_	_	_	_
24-17	4171-4175	been	_	_	_	_
24-18	4176-4186	associated	_	_	_	_
24-19	4187-4191	with	_	_	_	_
24-20	4192-4200	presence	abstract[197]	new[197]	_	_
24-21	4201-4203	of	abstract[197]	new[197]	_	_
24-22	4204-4207	the	abstract[197]|abstract[198]	new[197]|giv[198]	_	_
24-23	4208-4215	disease	abstract[197]|abstract[198]	new[197]|giv[198]	_	_
24-24	4216-4217	,	abstract[197]	new[197]	_	_
24-25	4218-4227	including	abstract[197]	new[197]	_	_
24-26	4228-4231	age	abstract[197]|abstract	new[197]|giv	_	_
24-27	4232-4233	,	abstract[197]	new[197]	_	_
24-28	4234-4237	sex	abstract[197]|abstract	new[197]|new	_	_
24-29	4238-4239	,	abstract[197]	new[197]	_	_
24-30	4240-4247	obesity	abstract[197]|abstract	new[197]|new	coref	27-4
24-31	4248-4249	,	abstract[197]	new[197]	_	_
24-32	4250-4253	and	abstract[197]	new[197]	_	_
24-33	4254-4258	diet	abstract[197]|event	new[197]|new	coref	28-3
24-34	4259-4260	,	abstract[197]	new[197]	_	_
24-35	4261-4264	and	abstract[197]	new[197]	_	_
24-36	4265-4270	local	abstract[197]|event[203]	new[197]|new[203]	_	_
24-37	4271-4276	joint	abstract[197]|event[203]	new[197]|new[203]	_	_
24-38	4277-4283	injury	abstract[197]|event[203]	new[197]|new[203]	_	_
24-39	4284-4285	.	_	_	_	_

#Text=Most of these factors are associated with drastic changes in the intestinal microbiota .
25-1	4286-4290	Most	abstract[204]	giv[204]	coref	29-25[246_204]
25-2	4291-4293	of	abstract[204]	giv[204]	_	_
25-3	4294-4299	these	abstract[204]	giv[204]	_	_
25-4	4300-4307	factors	abstract[204]	giv[204]	_	_
25-5	4308-4311	are	_	_	_	_
25-6	4312-4322	associated	_	_	_	_
25-7	4323-4327	with	_	_	_	_
25-8	4328-4335	drastic	abstract[205]	new[205]	coref	27-8[222_205]
25-9	4336-4343	changes	abstract[205]	new[205]	_	_
25-10	4344-4346	in	abstract[205]	new[205]	_	_
25-11	4347-4350	the	abstract[205]|abstract[206]	new[205]|giv[206]	coref	26-7[208_206]
25-12	4351-4361	intestinal	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
25-13	4362-4372	microbiota	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
25-14	4373-4374	.	_	_	_	_

#Text=Age , in fact , shifts the intestinal microbiota with significant differences between younger adults and older people , showing a lower diversity of gut microbiota , a greater proportion of Bacteroides spp. , and a distinct abundance pattern of Clostridium groups .
26-1	4375-4378	Age	abstract	new	_	_
26-2	4379-4380	,	_	_	_	_
26-3	4381-4383	in	_	_	_	_
26-4	4384-4388	fact	_	_	_	_
26-5	4389-4390	,	_	_	_	_
26-6	4391-4397	shifts	_	_	_	_
26-7	4398-4401	the	abstract[208]	giv[208]	coref	26-25[214_208]
26-8	4402-4412	intestinal	abstract[208]	giv[208]	_	_
26-9	4413-4423	microbiota	abstract[208]	giv[208]	_	_
26-10	4424-4428	with	abstract[208]	giv[208]	_	_
26-11	4429-4440	significant	abstract[208]|abstract[209]	giv[208]|new[209]	_	_
26-12	4441-4452	differences	abstract[208]|abstract[209]	giv[208]|new[209]	_	_
26-13	4453-4460	between	abstract[208]|abstract[209]	giv[208]|new[209]	_	_
26-14	4461-4468	younger	abstract[208]|abstract[209]|person[210]	giv[208]|new[209]|new[210]	_	_
26-15	4469-4475	adults	abstract[208]|abstract[209]|person[210]	giv[208]|new[209]|new[210]	_	_
26-16	4476-4479	and	abstract[208]|abstract[209]	giv[208]|new[209]	_	_
26-17	4480-4485	older	abstract[208]|abstract[209]|person[211]	giv[208]|new[209]|new[211]	_	_
26-18	4486-4492	people	abstract[208]|abstract[209]|person[211]	giv[208]|new[209]|new[211]	_	_
26-19	4493-4494	,	_	_	_	_
26-20	4495-4502	showing	_	_	_	_
26-21	4503-4504	a	abstract[212]	new[212]	coref	27-23[226_212]
26-22	4505-4510	lower	abstract[212]	new[212]	_	_
26-23	4511-4520	diversity	abstract[212]	new[212]	_	_
26-24	4521-4523	of	abstract[212]	new[212]	_	_
26-25	4524-4527	gut	abstract[212]|abstract|abstract[214]	new[212]|giv|giv[214]	coref|coref|coref|coref	27-11[223_214]|28-6|27-11[223_214]|28-6
26-26	4528-4538	microbiota	abstract[212]|abstract[214]	new[212]|giv[214]	_	_
26-27	4539-4540	,	_	_	_	_
26-28	4541-4542	a	quantity[215]	new[215]	_	_
26-29	4543-4550	greater	quantity[215]	new[215]	_	_
26-30	4551-4561	proportion	quantity[215]	new[215]	_	_
26-31	4562-4564	of	quantity[215]	new[215]	_	_
26-32	4565-4576	Bacteroides	quantity[215]|place	new[215]|giv	_	_
26-33	4577-4581	spp.	quantity[215]	new[215]	_	_
26-34	4582-4583	,	_	_	_	_
26-35	4584-4587	and	_	_	_	_
26-36	4588-4589	a	abstract[218]	new[218]	_	_
26-37	4590-4598	distinct	abstract[218]	new[218]	_	_
26-38	4599-4608	abundance	abstract|abstract[218]	new|new[218]	_	_
26-39	4609-4616	pattern	abstract[218]	new[218]	_	_
26-40	4617-4619	of	abstract[218]	new[218]	_	_
26-41	4620-4631	Clostridium	abstract[218]|organization|person[220]	new[218]|new|new[220]	_	_
26-42	4632-4638	groups	abstract[218]|person[220]	new[218]|new[220]	_	_
26-43	4639-4640	.	_	_	_	_

#Text=In addition , obesity is associated with phylum-level changes in the microbiota ( i. e. , ratio of Firmicutes/Bacteroidetes ) , reduced bacterial diversity , and an altered representation of bacterial genes and metabolic pathways .
27-1	4641-4643	In	_	_	_	_
27-2	4644-4652	addition	_	_	_	_
27-3	4653-4654	,	_	_	_	_
27-4	4655-4662	obesity	abstract	giv	_	_
27-5	4663-4665	is	_	_	_	_
27-6	4666-4676	associated	_	_	_	_
27-7	4677-4681	with	_	_	_	_
27-8	4682-4694	phylum-level	abstract[222]	giv[222]	_	_
27-9	4695-4702	changes	abstract[222]	giv[222]	_	_
27-10	4703-4705	in	abstract[222]	giv[222]	_	_
27-11	4706-4709	the	abstract[222]|abstract[223]	giv[222]|giv[223]	appos	27-17[224_223]
27-12	4710-4720	microbiota	abstract[222]|abstract[223]	giv[222]|giv[223]	_	_
27-13	4721-4722	(	abstract[222]	giv[222]	_	_
27-14	4723-4725	i.	abstract[222]	giv[222]	_	_
27-15	4726-4728	e.	abstract[222]	giv[222]	_	_
27-16	4729-4730	,	abstract[222]	giv[222]	_	_
27-17	4731-4736	ratio	abstract[222]|abstract[224]	giv[222]|giv[224]	coref	28-6[233_224]
27-18	4737-4739	of	abstract[222]|abstract[224]	giv[222]|giv[224]	_	_
27-19	4740-4764	Firmicutes/Bacteroidetes	abstract[222]|abstract[224]|substance	giv[222]|giv[224]|new	_	_
27-20	4765-4766	)	abstract[222]	giv[222]	_	_
27-21	4767-4768	,	abstract[222]	giv[222]	_	_
27-22	4769-4776	reduced	abstract[222]	giv[222]	_	_
27-23	4777-4786	bacterial	abstract[222]|abstract[226]	giv[222]|giv[226]	_	_
27-24	4787-4796	diversity	abstract[222]|abstract[226]	giv[222]|giv[226]	_	_
27-25	4797-4798	,	abstract[222]	giv[222]	_	_
27-26	4799-4802	and	abstract[222]	giv[222]	_	_
27-27	4803-4805	an	abstract[222]|abstract[227]	giv[222]|new[227]	_	_
27-28	4806-4813	altered	abstract[222]|abstract[227]	giv[222]|new[227]	_	_
27-29	4814-4828	representation	abstract[222]|abstract[227]	giv[222]|new[227]	_	_
27-30	4829-4831	of	abstract[222]|abstract[227]	giv[222]|new[227]	_	_
27-31	4832-4841	bacterial	abstract[222]|abstract[227]|substance|abstract[229]	giv[222]|new[227]|giv|new[229]	_	_
27-32	4842-4847	genes	abstract[222]|abstract[227]|abstract[229]	giv[222]|new[227]|new[229]	_	_
27-33	4848-4851	and	abstract[222]|abstract[227]	giv[222]|new[227]	_	_
27-34	4852-4861	metabolic	abstract[222]|abstract[227]|abstract[230]	giv[222]|new[227]|new[230]	_	_
27-35	4862-4870	pathways	abstract[222]|abstract[227]|abstract[230]	giv[222]|new[227]|new[230]	_	_
27-36	4871-4872	.	_	_	_	_

#Text=Finally , diet can shape gut microbiota and consequently change the composition and metabolism of intestinal microbiota as well as impact host immune responses .
28-1	4873-4880	Finally	_	_	_	_
28-2	4881-4882	,	_	_	_	_
28-3	4883-4887	diet	event	giv	coref	31-13[255_0]
28-4	4888-4891	can	_	_	_	_
28-5	4892-4897	shape	_	_	_	_
28-6	4898-4901	gut	abstract|abstract[233]	giv|giv[233]	coref|coref|coref|coref	28-16[236_233]|30-14|28-16[236_233]|30-14
28-7	4902-4912	microbiota	abstract[233]	giv[233]	_	_
28-8	4913-4916	and	_	_	_	_
28-9	4917-4929	consequently	_	_	_	_
28-10	4930-4936	change	_	_	_	_
28-11	4937-4940	the	abstract[234]	new[234]	_	_
28-12	4941-4952	composition	abstract[234]	new[234]	_	_
28-13	4953-4956	and	_	_	_	_
28-14	4957-4967	metabolism	abstract[235]	new[235]	_	_
28-15	4968-4970	of	abstract[235]	new[235]	_	_
28-16	4971-4981	intestinal	abstract[235]|abstract[236]	new[235]|giv[236]	coref	30-14[252_236]
28-17	4982-4992	microbiota	abstract[235]|abstract[236]	new[235]|giv[236]	_	_
28-18	4993-4995	as	_	_	_	_
28-19	4996-5000	well	_	_	_	_
28-20	5001-5003	as	_	_	_	_
28-21	5004-5010	impact	abstract[239]	new[239]	_	_
28-22	5011-5015	host	person|abstract[239]	new|new[239]	_	_
28-23	5016-5022	immune	abstract|abstract[239]	giv|new[239]	_	_
28-24	5023-5032	responses	abstract[239]	new[239]	_	_
28-25	5033-5034	.	_	_	_	_

#Text=For these reasons , OA is now considered an induced inflammatory condition in which the role of the microbiome has emerging as one of the most important factors .
29-1	5035-5038	For	_	_	_	_
29-2	5039-5044	these	abstract[240]	new[240]	_	_
29-3	5045-5052	reasons	abstract[240]	new[240]	_	_
29-4	5053-5054	,	_	_	_	_
29-5	5055-5057	OA	abstract	giv	coref	31-71[276_0]
29-6	5058-5060	is	_	_	_	_
29-7	5061-5064	now	_	_	_	_
29-8	5065-5075	considered	_	_	_	_
29-9	5076-5078	an	abstract[242]	new[242]	_	_
29-10	5079-5086	induced	abstract[242]	new[242]	_	_
29-11	5087-5099	inflammatory	abstract[242]	new[242]	_	_
29-12	5100-5109	condition	abstract[242]	new[242]	_	_
29-13	5110-5112	in	_	_	_	_
29-14	5113-5118	which	_	_	_	_
29-15	5119-5122	the	abstract[243]	new[243]	_	_
29-16	5123-5127	role	abstract[243]	new[243]	_	_
29-17	5128-5130	of	abstract[243]	new[243]	_	_
29-18	5131-5134	the	abstract[243]|object[244]	new[243]|giv[244]	_	_
29-19	5135-5145	microbiome	abstract[243]|object[244]	new[243]|giv[244]	_	_
29-20	5146-5149	has	_	_	_	_
29-21	5150-5158	emerging	_	_	_	_
29-22	5159-5161	as	_	_	_	_
29-23	5162-5165	one	abstract[245]	new[245]	_	_
29-24	5166-5168	of	abstract[245]	new[245]	_	_
29-25	5169-5172	the	abstract[245]|abstract[246]	new[245]|giv[246]	_	_
29-26	5173-5177	most	abstract[245]|abstract[246]	new[245]|giv[246]	_	_
29-27	5178-5187	important	abstract[245]|abstract[246]	new[245]|giv[246]	_	_
29-28	5188-5195	factors	abstract[245]|abstract[246]	new[245]|giv[246]	_	_
29-29	5196-5197	.	_	_	_	_

#Text=Several publications have reported a clear demonstration of the link between osteoarthritis and gut microbiota .
30-1	5198-5205	Several	organization[247]	new[247]	_	_
30-2	5206-5218	publications	organization[247]	new[247]	_	_
30-3	5219-5223	have	_	_	_	_
30-4	5224-5232	reported	_	_	_	_
30-5	5233-5234	a	event[248]	new[248]	_	_
30-6	5235-5240	clear	event[248]	new[248]	_	_
30-7	5241-5254	demonstration	event[248]	new[248]	_	_
30-8	5255-5257	of	event[248]	new[248]	_	_
30-9	5258-5261	the	event[248]|abstract[249]	new[248]|new[249]	_	_
30-10	5262-5266	link	event[248]|abstract[249]	new[248]|new[249]	_	_
30-11	5267-5274	between	event[248]|abstract[249]	new[248]|new[249]	_	_
30-12	5275-5289	osteoarthritis	event[248]|abstract[249]|abstract	new[248]|new[249]|new	coref	31-18
30-13	5290-5293	and	event[248]|abstract[249]	new[248]|new[249]	_	_
30-14	5294-5297	gut	event[248]|abstract[249]|abstract|abstract[252]	new[248]|new[249]|giv|giv[252]	_	_
30-15	5298-5308	microbiota	event[248]|abstract[249]|abstract[252]	new[248]|new[249]|giv[252]	_	_
30-16	5309-5310	.	_	_	_	_

#Text=For instance , animals with a low-grade chronic systemic inflammation due to a high-fat diet have developed osteoarthritis , and others with an increased body weight due to diet have shown an increased progression of osteoarthritis . Metcalfe et al. proposed that metabolic endotoxemia ( raised LPS blood and synovial concentrations ) caused by impaired gastric mucosa and low-grade chronic inflammation , may contribute to the onset and progression of OA in obese patients .
31-1	5311-5314	For	_	_	_	_
31-2	5315-5323	instance	_	_	_	_
31-3	5324-5325	,	_	_	_	_
31-4	5326-5333	animals	animal[253]	new[253]	_	_
31-5	5334-5338	with	animal[253]	new[253]	_	_
31-6	5339-5340	a	animal[253]|abstract[254]	new[253]|giv[254]	coref	31-59[273_254]
31-7	5341-5350	low-grade	animal[253]|abstract[254]	new[253]|giv[254]	_	_
31-8	5351-5358	chronic	animal[253]|abstract[254]	new[253]|giv[254]	_	_
31-9	5359-5367	systemic	animal[253]|abstract[254]	new[253]|giv[254]	_	_
31-10	5368-5380	inflammation	animal[253]|abstract[254]	new[253]|giv[254]	_	_
31-11	5381-5384	due	_	_	_	_
31-12	5385-5387	to	_	_	_	_
31-13	5388-5389	a	event[255]	giv[255]	coref	31-29[0_255]
31-14	5390-5398	high-fat	event[255]	giv[255]	_	_
31-15	5399-5403	diet	event[255]	giv[255]	_	_
31-16	5404-5408	have	_	_	_	_
31-17	5409-5418	developed	_	_	_	_
31-18	5419-5433	osteoarthritis	abstract	giv	coref	31-36
31-19	5434-5435	,	_	_	_	_
31-20	5436-5439	and	_	_	_	_
31-21	5440-5446	others	person[257]	new[257]	_	_
31-22	5447-5451	with	person[257]	new[257]	_	_
31-23	5452-5454	an	person[257]|abstract[259]	new[257]|new[259]	_	_
31-24	5455-5464	increased	person[257]|abstract[259]	new[257]|new[259]	_	_
31-25	5465-5469	body	person[257]|object|abstract[259]	new[257]|new|new[259]	_	_
31-26	5470-5476	weight	person[257]|abstract[259]	new[257]|new[259]	_	_
31-27	5477-5480	due	person[257]|abstract[259]	new[257]|new[259]	_	_
31-28	5481-5483	to	_	_	_	_
31-29	5484-5488	diet	event	giv	_	_
31-30	5489-5493	have	_	_	_	_
31-31	5494-5499	shown	_	_	_	_
31-32	5500-5502	an	abstract[261]	new[261]	_	_
31-33	5503-5512	increased	abstract[261]	new[261]	_	_
31-34	5513-5524	progression	abstract[261]	new[261]	_	_
31-35	5525-5527	of	abstract[261]	new[261]	_	_
31-36	5528-5542	osteoarthritis	abstract[261]|abstract	new[261]|giv	_	_
31-37	5543-5544	.	_	_	_	_
31-38	5545-5553	Metcalfe	person	new	_	_
31-39	5554-5556	et	_	_	_	_
31-40	5557-5560	al.	_	_	_	_
31-41	5561-5569	proposed	_	_	_	_
31-42	5570-5574	that	_	_	_	_
31-43	5575-5584	metabolic	person|abstract[265]	new|new[265]	_	_
31-44	5585-5596	endotoxemia	abstract[265]	new[265]	_	_
31-45	5597-5598	(	_	_	_	_
31-46	5599-5605	raised	_	_	_	_
31-47	5606-5609	LPS	animal|substance[267]	new|new[267]	_	_
31-48	5610-5615	blood	substance[267]	new[267]	_	_
31-49	5616-5619	and	_	_	_	_
31-50	5620-5628	synovial	substance|animal[269]	new|giv[269]	_	_
31-51	5629-5643	concentrations	animal[269]	giv[269]	_	_
31-52	5644-5645	)	_	_	_	_
31-53	5646-5652	caused	_	_	_	_
31-54	5653-5655	by	_	_	_	_
31-55	5656-5664	impaired	object[271]	new[271]	_	_
31-56	5665-5672	gastric	abstract|object[271]	new|new[271]	_	_
31-57	5673-5679	mucosa	object[271]	new[271]	_	_
31-58	5680-5683	and	_	_	_	_
31-59	5684-5693	low-grade	abstract[273]	giv[273]	_	_
31-60	5694-5701	chronic	abstract|abstract[273]	new|giv[273]	_	_
31-61	5702-5714	inflammation	abstract[273]	giv[273]	_	_
31-62	5715-5716	,	_	_	_	_
31-63	5717-5720	may	_	_	_	_
31-64	5721-5731	contribute	_	_	_	_
31-65	5732-5734	to	_	_	_	_
31-66	5735-5738	the	abstract[274]	giv[274]	_	_
31-67	5739-5744	onset	abstract[274]	giv[274]	_	_
31-68	5745-5748	and	_	_	_	_
31-69	5749-5760	progression	abstract[275]	new[275]	_	_
31-70	5761-5763	of	abstract[275]	new[275]	_	_
31-71	5764-5766	OA	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
31-72	5767-5769	in	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
31-73	5770-5775	obese	abstract[275]|abstract[276]|person[277]	new[275]|giv[276]|giv[277]	_	_
31-74	5776-5784	patients	abstract[275]|abstract[276]|person[277]	new[275]|giv[276]|giv[277]	_	_
31-75	5785-5786	.	_	_	_	_
